Bronte, G.; Cosi, D.M.; Magri, C.; Frassoldati, A.; Crinò, L.; Calabrò, L. Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? Int. J. Mol. Sci.2023, 24, 12622.
Bronte, G.; Cosi, D.M.; Magri, C.; Frassoldati, A.; Crinò, L.; Calabrò, L. Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? Int. J. Mol. Sci. 2023, 24, 12622.
Bronte, G.; Cosi, D.M.; Magri, C.; Frassoldati, A.; Crinò, L.; Calabrò, L. Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? Int. J. Mol. Sci.2023, 24, 12622.
Bronte, G.; Cosi, D.M.; Magri, C.; Frassoldati, A.; Crinò, L.; Calabrò, L. Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? Int. J. Mol. Sci. 2023, 24, 12622.
Abstract
Over the last decade, the therapeutic scenario for advanced non-small-cell lung cancer (NSCLC) has undergone a major paradigm shift. Immune checkpoint inhibitors (ICIs) have shown a meaningful clinical and survival improvement in different settings of the disease. However, the real benefit of this therapeutic approach remains controversial in selected NSCLC subsets, such as those of the elderly with active brain metastases or oncogene-addicted mutations. This is mainly due to the exclusion or underrepresentation of these patient subpopulations in most of the pivotal phase III studies; this precludes the generalization of the ICI efficacy in this context. Moreover, no predictive biomarkers of ICI response exist that can help with patient selection for this therapeutic approach. Here, we critically summarize the current state of ICI efficacy in the most common “special” NSCLC subpopulations.
Keywords
NSCLC,; Immunotherapy; Immune Checkpoint Inhibitors; Special populations
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
